Grade Group 5 is the highest prostate cancer grade and corresponds to Gleason scores of 9 or 10. It includes Gleason 4+5=9, 5+4=9 and 5+5=10, all of which contain pattern 5 cancer.
Grade Group 5 has a greater risk of growth, spread and recurrence than lower Grade Groups. However, it does not automatically mean that the cancer has spread, and localised or locally advanced disease may still be treated with curative intent.
What Does Grade Group 5 Mean?
Prostate cancer is divided into five Grade Groups, with Grade Group 1 representing the lowest category normally diagnosed and Grade Group 5 representing the highest-grade disease. Grade Group 5 contains Gleason pattern 5, which shows little or no recognisable gland formation under the microscope.
Grade Group 5 has a greater risk of growth, spread and recurrence than the lower Grade Groups, but it does not determine your prognosis by itself. Your PSA level, clinical stage, imaging, biopsy findings, general health and response to treatment also influence your outlook.
Which Gleason Scores Are Grade Group 5?
Grade Group 5 includes Gleason 4+5=9, 5+4=9 and 5+5=10. All these combinations contain Gleason pattern 5, which shows the greatest loss of normal gland structure.
Gleason 5+5=10 means that both reported components are pattern 5. Although all three scores belong to Grade Group 5, the individual pattern combination may provide additional prognostic information.
Why Does the Order of the Numbers Matter?
The first Gleason number generally represents the predominant cancer pattern in the tissue being graded. The second records the additional pattern used to calculate the score, with needle-biopsy rules ensuring that an important higher-grade component is included.
Gleason 4+5 and 5+4 both total nine, but pattern 5 is predominant in 5+4. Research suggests that the different Grade Group 5 combinations may have different outcomes, although treatment decisions must still consider the complete clinical assessment.
How Is Grade Group 5 Diagnosed?
Grade Group 5 is diagnosed when a pathologist examines prostate tissue collected during a biopsy and identifies a Gleason score of 4+5=9, 5+4=9 or 5+5=10. These scores describe the microscopic growth patterns found in the sampled cancer.
Your pathology report may also describe how many biopsy samples contain cancer, how much cancer is present and whether other relevant pathological features have been identified. The results are considered alongside your PSA level, MRI and staging investigations when planning treatment.
Can an MRI Show Grade Group 5?
An MRI can help you identify suspicious areas in your prostate, show where the cancer may be located and guide a targeted biopsy. However, it cannot confirm Grade Group 5 on its own because the tissue must be examined under a microscope.
MRI remains an important part of your assessment because it can help show whether the cancer may have grown beyond the prostate or affected nearby structures. This information helps your specialist plan the most appropriate next steps for you.
Is Grade Group 5 the Same as Stage 5?
No. Prostate cancer does not have a standard stage 5 category. Grade Group 5 describes the cancer’s microscopic growth patterns and likely biological behaviour.
Your TNM stage is a separate assessment that shows where your cancer is located, whether it has grown outside the prostate, whether lymph nodes are involved and whether it has spread to distant parts of your body. Both grade and stage are needed to understand your overall diagnosis.
Does Grade Group 5 Mean the Cancer Has Spread?
Grade Group 5 does not automatically mean that prostate cancer has spread beyond the prostate. However, because it is the highest grade category and has a greater risk of aggressive behaviour, your specialist may recommend staging tests to check the extent of the cancer.
Understanding Grade Group 5 and Cancer Spread
| Aspect | What It Means | Why It Matters | What May Happen Next |
| Grade Group 5 diagnosis | The biopsy contains the highest-grade microscopic growth patterns | Indicates a greater risk of progression than lower Grade Groups | Requires staging and multidisciplinary treatment planning |
| Cancer location | The cancer may still be contained within the prostate | Grade does not show whether cancer has spread | Staging tests are needed to check the extent |
| Risk of spread | Higher-grade cancers have a greater chance of growing or spreading | Helps doctors understand potential behaviour | May influence treatment recommendations |
| Staging tests | May include scans and other investigations | Shows whether cancer is localised or has spread | Helps guide the most suitable treatment approach |
| Treatment planning | Decisions depend on grade, stage, PSA and overall health | Ensures care is personalised | Your specialist will discuss available options |
| Individual outlook | Each person’s cancer behaves differently | Grade Group alone does not determine your outcome | Your full diagnosis provides a clearer picture |
What Is Cambridge Prognostic Group 5?
Grade Group 5 automatically places non-metastatic prostate cancer in Cambridge Prognostic Group 5. CPG 5 also includes stage T4 cancer or cancer with at least two CPG 4 features, such as Grade Group 4, PSA above 20 ng/ml or stage T3.
The CPG system is designed for prostate cancer that has not spread to distant parts of the body. Once metastatic disease is confirmed, treatment planning is based mainly on the stage, extent of spread, hormone sensitivity, symptoms and previous treatment.
UK Guidance Note
Current NICE guidance states that active surveillance should not be offered for CPG 4 or CPG 5 localised or locally advanced prostate cancer. Radical prostatectomy or radical radiotherapy should be offered when long-term cancer control is considered achievable and treatment is suitable for the person’s health and circumstances.
When radical external beam radiotherapy is selected for CPG 5 disease, it should be combined with androgen deprivation therapy. NICE recommends offering six months of hormone therapy and considering continuation for up to three years after discussing the potential benefits and side effects.
What Is the Outlook?
Grade Group 5 prostate cancer has a higher risk of progression, spread and recurrence compared with lower-grade disease. However, your Grade Group alone cannot predict exactly how your cancer will behave or what your outcome will be.
Your individual outlook depends on several factors, including your cancer stage, PSA level, scan results, response to treatment, age and general health. Your specialist will consider all of these factors when discussing your prognosis with you.
Can Grade Group 5 Be Treated With Curative Intent?
Localised or locally advanced Grade Group 5 prostate cancer may be treated with curative intent when your multidisciplinary team believes that long-term cancer control is achievable.
Possible treatments include radical prostatectomy or radical radiotherapy combined with hormone therapy. No treatment can guarantee a cure, and the recommendation depends on your stage, general health, expected treatment benefit and personal priorities.
Is Active Surveillance Appropriate?
Active surveillance is not recommended if you have Grade Group 5 or CPG 5 prostate cancer. This is because the risk of progression is considered too high for a monitoring-only approach.
Your specialist will usually discuss active treatment options with you if you are medically suitable and long-term cancer control is considered possible. The recommended treatment will depend on your cancer stage, overall health and personal circumstances.
Is Radical Prostatectomy an Option?
Radical prostatectomy may be considered if your Grade Group 5 prostate cancer has not spread to distant areas and your specialist believes surgery could provide long-term control. During this operation, your prostate gland and usually the seminal vesicles are removed.
Your surgeon may also recommend removing nearby pelvic lymph nodes because Grade Group 5 cancer has a higher risk of lymph-node involvement. The results can help confirm your stage and guide any further treatment decisions.
Could You Need Treatment After Surgery?
Your PSA should fall to a very low or undetectable level after radical prostatectomy. A PSA that remains detectable or rises during follow-up may lead to further imaging and discussion of salvage radiotherapy, sometimes combined with hormone therapy.
Positive surgical margins, cancer beyond the prostate or involved lymph nodes increase the risk of recurrence, but they do not automatically mean that immediate radiotherapy is required. Your multidisciplinary team will consider the surgical pathology, postoperative PSA pattern and imaging before recommending further treatment.
Is Radiotherapy an Option?
Radical external beam radiotherapy is an established option for suitable CPG 5 localised or locally advanced prostate cancer. Treatment may include the prostate, seminal vesicles and selected nearby lymph nodes according to the estimated risk of involvement.
Radiotherapy is normally combined with androgen deprivation therapy. Possible effects include urinary and bowel symptoms, fatigue, erectile dysfunction and hormone-related side effects.
How Long Is Hormone Therapy Given?
If you have CPG 5 prostate cancer and are receiving radical external beam radiotherapy, NICE recommends combining radiotherapy with androgen deprivation therapy. Six months should be offered before, during or after radiotherapy, and continuation for up to three years may be considered after discussing the potential benefits and risks.
- Treatment duration: Hormone therapy length depends on your cancer risk group, treatment plan and individual circumstances
- Radiotherapy support: For CPG 5 disease, NICE recommends combining androgen deprivation therapy with radical external beam radiotherapy.
- Testosterone control: Hormone therapy lowers testosterone levels, which prostate cancer cells often use to grow
- Side effects: You may experience hot flushes, tiredness, reduced sexual desire, bone thinning and body composition changes
- Specialist guidance: Your doctor will balance the potential benefits and risks when deciding how long treatment should continue
The duration of hormone therapy varies from person to person and depends on factors such as your cancer stage, grade and overall health. Regular discussions with your specialist can help you understand your treatment plan and manage any side effects effectively.
Can Brachytherapy Be Used?
Brachytherapy may be considered in combination with external beam radiotherapy for selected people with CPG 5 localised or locally advanced prostate cancer. It should not be offered as the only form of radiotherapy for CPG 5 disease.
Suitability depends on your urinary function, prostate size and anatomy, cancer extent, previous prostate procedures, general health and the expertise available. Hormone therapy would normally also form part of the radical radiotherapy plan.
Is Chemotherapy Sometimes Recommended?
Docetaxel chemotherapy may be discussed if you have newly diagnosed high-risk, non-metastatic prostate cancer and are starting long-term hormone therapy. Your overall fitness, general health and any other medical conditions will be considered before recommending this option.
If you have newly diagnosed metastatic prostate cancer, you may also be offered docetaxel alongside hormone therapy if you are fit enough to tolerate treatment. Your specialist will discuss the potential benefits, risks and suitability with you.
How Is Metastatic Grade Group 5 Cancer Treated?
Treatment for metastatic prostate cancer usually includes ongoing androgen deprivation therapy, often combined with another systemic treatment such as an androgen-receptor pathway medicine or docetaxel chemotherapy. The choice depends on whether the cancer remains hormone-sensitive, the amount and location of spread, previous treatments and your general health.
Radiotherapy to the prostate may be considered in selected people with newly diagnosed lower-volume metastatic disease. Radiotherapy can also treat painful bone disease or other symptoms, while targeted treatments may be available for some cancers with particular genetic alterations.
How Will You Be Monitored?
After treatment, you will usually have regular PSA blood tests to check how well your cancer is responding. Your specialist may also arrange further imaging if your PSA level rises, you develop new symptoms or there is concern that the cancer may be progressing.
You should ask for your exact Grade Group, Gleason score, PSA level and TNM stage. If your cancer is non-metastatic, also ask for your Cambridge Prognostic Group. Understanding these results can help you see why a particular treatment plan has been recommended for you.
Myth vs Fact
| Myth | Fact |
| Grade Group 5 means the cancer has already spread. | Grade describes the cancer’s microscopic growth pattern and cannot determine where the cancer is located. |
| Grade Group 5 is the same as stage 5 cancer. | Prostate cancer has no standard stage 5 category. |
| Every Grade Group 5 cancer is untreatable. | Non-metastatic disease may be treated with surgery or radical radiotherapy. |
| Gleason 4+5 and 5+4 are identical. | Both belong to Grade Group 5, but 5+4 contains predominantly pattern 5. |
| Active surveillance is an appropriate option. | NICE advises against active surveillance for CPG 5 disease. |
| Surgery alone is always sufficient. | Some patients require additional treatment according to pathology and postoperative PSA. |
| Positive surgical margins automatically require immediate radiotherapy. | NICE does not recommend routine immediate postoperative radiotherapy solely for positive margins. |
| Every patient with metastatic cancer receives the same treatment. | Treatment depends on hormone sensitivity, extent of spread, health, genetics and previous therapies. |
Key Takeaways
- Grade Group 5 corresponds to Gleason 4+5=9, 5+4=9 or 5+5=10.
- It is the highest prostate cancer grade and always contains pattern 5.
- Grade Group 5 is not the same as metastatic or stage 4 prostate cancer.
- Non-metastatic Grade Group 5 cancer is classified as CPG 5.
- Localised or locally advanced disease may still be treated with curative intent.
- Active surveillance is not recommended for Grade Group 5.
- Surgery may be considered as part of a multimodal treatment plan.
- Radical radiotherapy is normally combined with hormone therapy.
- Immediate radiotherapy is not routinely given after surgery solely because margins are positive.
- Metastatic treatment depends on hormone sensitivity, extent of spread, previous treatment and general health.
Frequently Asked Questions
- What Does Grade Group 5 Prostate Cancer Mean?
Grade Group 5 is the highest prostate cancer grade and corresponds to Gleason scores of 9 or 10. It contains Gleason pattern 5 and has a greater risk of progression than the lower Grade Groups. - Which Gleason Scores Are Grade Group 5?
Grade Group 5 includes Gleason 4+5=9, 5+4=9 and 5+5=10. These combinations all contain pattern 5, although the predominant pattern differs. - Is Grade Group 5 the Same as Stage 5 Prostate Cancer?
No, Grade Group 5 and Stage 5 are not the same. Grade Group 5 describes the microscopic growth patterns and likely behaviour of the cancer, while staging describes its location and whether it has spread. - Does Grade Group 5 Mean the Cancer Has Spread?
No, Grade Group 5 does not automatically mean your cancer has spread. Your cancer may still be confined to the prostate, but detailed staging tests are usually needed. - How Is Grade Group 5 Prostate Cancer Diagnosed?
Grade Group 5 is diagnosed through a prostate biopsy, where a pathologist examines your tissue samples under a microscope. The Gleason score from this assessment determines your Grade Group. - Can Grade Group 5 Prostate Cancer Be Cured?
Localised or locally advanced Grade Group 5 cancer may be treated with curative intent using surgery or radical radiotherapy combined with hormone therapy. No treatment can guarantee a cure. - Is Surgery an Option for Grade Group 5 Prostate Cancer?
Radical prostatectomy may be considered for selected non-metastatic Grade Group 5 cancers when surgery forms part of a plan for long-term cancer control. Pelvic lymph nodes may also be removed. - Will I Need Hormone Therapy for Grade Group 5 Prostate Cancer?
Hormone therapy is normally combined with radical external beam radiotherapy. NICE recommends offering six months and considering continuation for up to three years for CPG 5 disease. - What Is the Outlook for Grade Group 5 Prostate Cancer?
Grade Group 5 has a higher risk of progression, spread and recurrence compared with lower-grade cancers. Your outlook depends on factors such as stage, PSA level, scan results, treatment response and overall health. - How Is Metastatic Grade Group 5 Prostate Cancer Treated?
Metastatic disease is usually treated with androgen deprivation therapy combined with another systemic treatment when appropriate. Options may include newer hormone-blocking medicines, chemotherapy, radiotherapy and targeted treatments for selected cancers.
Final Thoughts: Grade Group 5 Prostate Cancer
Grade Group 5 is the highest prostate cancer grade and has a greater risk of growth, spread and recurrence than the lower Grade Groups. However, it does not automatically mean that the cancer has spread or that treatment with curative intent is no longer possible. Your PSA level, clinical stage, imaging, biopsy findings and general health provide a more complete picture.
If you are considering prostate cancer surgery in London, you can reach out to us to arrange a consultation and receive personalised advice about your diagnosis, treatment choices, and recovery.
References
- Cancer Research UK (2025) Cambridge prognostic groups and risk groups for prostate cancer. Last reviewed 22 May 2025. Available at: https://www.cancerresearchuk.org/about-cancer/prostate-cancer/stages/cambridge-prognostic-group-cpg
- Cancer Research UK (2025) Chemotherapy for prostate cancer. Last reviewed 28 July 2025. Available at: https://www.cancerresearchuk.org/about-cancer/prostate-cancer/metastatic-cancer/treatment/chemotherapy
- Cancer Research UK (2025) Hormone therapy for metastatic prostate cancer. Last reviewed 29 July 2025. Available at: https://www.cancerresearchuk.org/about-cancer/prostate-cancer/metastatic-cancer/treatment/hormone-therapy-for-metastatic-prostate-cancer
- Cancer Research UK (2025) Treatment for metastatic prostate cancer. Last reviewed 21 July 2025. Available at: https://www.cancerresearchuk.org/about-cancer/prostate-cancer/metastatic-cancer/treatment
- Cancer Research UK (2025) Treatment options for prostate cancer. Last reviewed 18 June 2025. Available at: https://www.cancerresearchuk.org/about-cancer/prostate-cancer/treatment/decisions-about-your-treatment
- Epstein, J.I., Egevad, L., Amin, M.B., Delahunt, B., Srigley, J.R. and Humphrey, P.A. (2016) ‘The 2014 International Society of Urological Pathology consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system’, The American Journal of Surgical Pathology, 40(2), pp. 244–252. Available at: https://pubmed.ncbi.nlm.nih.gov/26492179/
- National Institute for Health and Care Excellence (2019) Prostate cancer: diagnosis and management. NICE guideline NG131. Last updated 15 December 2021 and last reviewed 13 August 2025. Available at: https://www.nice.org.uk/guidance/ng131
- NHS (2025) Treatment for prostate cancer. Last reviewed 31 July 2025. Available at: https://www.nhs.uk/conditions/prostate-cancer/treatment/
- Prostate Cancer UK (2023) High dose-rate brachytherapy. Updated January 2023. Available at: https://prostatecanceruk.org/prostate-information-and-support/treatments/high-dose-rate-brachytherapy
- Prostate Cancer UK (2023) What do my test results mean? Updated August 2023. Available at: https://prostatecanceruk.org/prostate-information-and-support/just-diagnosed/what-do-my-test-results-mean
- Prostate Cancer UK (2024) Follow-up after prostate cancer treatment: What happens next? Updated March 2024. Available at: https://prostatecanceruk.org/prostate-information-and-support/treatments/follow-up-after-treatment
- Prostate Cancer UK (2024) Surgery: radical prostatectomy. Updated July 2024. Available at: https://prostatecanceruk.org/prostate-information-and-support/treatments/surgery
- Prostate Cancer UK (2026) External beam radiotherapy. Updated March 2026. Available at: https://prostatecanceruk.org/prostate-information-and-support/treatments/external-beam-radiotherapy
- Wenzel, M., Würnschimmel, C., Chierigo, F., Mori, K., Tian, Z., Terrone, C. et al. (2022) ‘Pattern of biopsy Gleason Grade Group 5 (4+5 vs 5+4 vs 5+5) predicts survival after radical prostatectomy or external-beam radiation therapy’, European Urology Focus, 8(3), pp. 710–717. Available at: https://pubmed.ncbi.nlm.nih.gov/33933420/